Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C

Study:

A Phase 2 Study of Telaprevir in Combination With Peginterferon Alfa-2a, and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy

Rationale:

n/a

Purpose:

The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with peginterferon alfa-2a (Pegasys®), and ribavirin (Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Hepatitis C Drug: Telaprevir
Drug: Ribavirin
Drug: Peg-interferon Alfa-2a
Drug: Matching Placebo
Phase 2

Verified by Vertex Pharmaceuticals Incorporated June, 2011

Sponsored by: Vertex Pharmaceuticals Incorporated
Information provided by: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov identifier: NCT00420784

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio
United States

Medical Monitor., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site